Login
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC.

sutrobio.com

What Do They Do?

Develops targeted cancer medicines that attach drugs to antibodies for patients with cancer, and protein-making technology for pharmaceutical and biotechnology partners.

Who Are Their Customers?

Pharmaceutical and biotechnology partners work with Sutro through product-focused collaborations and licenses; Vaxcyte receives technical support for vaccine research and development.

Do Revenues Turn Into Profits?

No. It lost $191.1M in FY2025.

Operating income, FY2025
−155% of revenue
▲ +34% (Loss) vs FY2024 (−$238.5M, −384%)
Net income, FY2025
−186% of revenue
▲ +16% (Loss) vs FY2024 (−$227.5M, −367%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −6%
vs $9.7M in Q3 FY2025
Net income
▲ +45% (Loss)
vs −$56.9M in Q3 FY2025

Pipeline focus The earlier report centered on luvelta for FolRα-expressing cancers; the latest centers on its tissue-factor ADC program and says luvelta development has ended.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support